Robert Jackson Mobley

Dr. Robert Jackson Mobley

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
PHPaul R. Hollis
Paul R. Hollis
RMRobert Jackson Mobley
Robert Jackson Mobley
JBJyoti Bhuju
Jyoti Bhuju
AAAmy N. Abell
Amy N. Abell
CSCarrie Hayes Sutter
Carrie Hayes Sutter
TSThomas Sutter
Thomas Sutter
Cytochrome P4501B1 (CYP1B1) is elevated in breast cancer. Studies indicate a relationship between CYP1B1 and aggressive cancer phenotypes. Here, we report on in vitro studies in triple-negative breast cancer cell lines, where knockdown (KD) of CYP1B1 was used to determine the influence of its expression on invasive cell phenotypes. CYP1B1 KD in MDA-MB-231 cells resulted in the loss of mesenchymal morphology, altered expression of epithelial–mesenchymal genes, and increased claudin (CLDN) RNA and protein. CYP1B1 KD cells had increased cell-to-cell contact and paracellular barrier function, a reduced rate of cell proliferation, abrogation of migratory and invasive activity, and diminished spheroid formation. Analysis of clinical breast cancer tumor samples revealed an association between tumors exhibiting higher CYP1B1 RNA levels and diminished overall and disease-free survival. Tumor expression of CYP1B1 was inversely associated with CLDN7 expression, and CYP1B1HI/CLDN7LOW identified patients with lower median survival. Cells with CYP1B1 KD had an enhanced chemosensitivity to paclitaxel, 5-fluorouracil, and cisplatin. Our findings that CYP1B1 KD can increase chemosensitivity points to therapeutic targeting of this enzyme. CYP1B1 inhibitors in combination with chemotherapeutic drugs may provide a novel targeted and effective approach to adjuvant or neoadjuvant therapy against certain forms of highly metastatic breast cancer.

24 August 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
PMPriya Mittal
Priya Mittal
JMJacquelyn A. Myers
Jacquelyn A. Myers
RCRaymond D. Carter
Raymond D. Carter
SRSandi Radko-Juettner
Sandi Radko-Juettner
HMHayden A. Malone
Hayden A. Malone
CRCharles W. M. Roberts
Charles W. M. Roberts
Genes encoding subunits of SWI/SNF (BAF) chromatin remodeling complexes are mutated in nearly 25% of cancers. To gain insight into the mechanisms by which SWI/SNF mutations drive cancer, we contributed ten rhabdoid tumor (RT) cell lines mutant for SWI/SNF subunit SMARCB1 to a genome-scale CRISPR–Cas9 depletion screen performed across 896 cell lines. We identify PHF6 as specifically essential for RT cell survival and demonstrate that dependency on Phf6 extends to Smarcb1-deficient cancers in vivo. As mutations in either SWI/SNF or PHF6 can cause the neurodevelopmental disorder Coffin-Siris syndrome, our findings of a dependency suggest a previously unrecognized functional link. We demonstrate that PHF6 co-localizes with SWI/SNF complexes at promoters, where it is essential for maintenance of an active chromatin state. We show that in the absence of SMARCB1, PHF6 loss disrupts the recruitment and stability of residual SWI/SNF complex members, collectively resulting in the loss of active chromatin at promoters and stalling of RNA Polymerase II progression. Our work establishes a mechanistic basis for the shared syndromic features of SWI/SNF and PHF6 mutations in CSS and the basis for selective dependency on PHF6 in SMARCB1-mutant cancers.

1 May 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
KBKashi Raj Bhattarai
Kashi Raj Bhattarai
RMRobert Jackson Mobley
Robert Jackson Mobley
KBKelly R. Barnett
Kelly R. Barnett
DFDaniel C. Ferguson
Daniel C. Ferguson
BHBaranda S. Hansen
Baranda S. Hansen
DSDaniel Savic
Daniel Savic
Defining genetic factors impacting chemotherapy failure can help to better predict response and identify drug resistance mechanisms. However, there is limited understanding of the contribution of inherited noncoding genetic variation on inter-individual differences in chemotherapy response in childhood acute lymphoblastic leukemia (ALL). Here we map inherited noncoding variants associated with treatment outcome and/or chemotherapeutic drug resistance to ALL cis-regulatory elements and investigate their gene regulatory potential and target gene connectivity using massively parallel reporter assays and three-dimensional chromatin looping assays, respectively. We identify 54 variants with transcriptional effects and high-confidence gene connectivity. Additionally, functional interrogation of the top variant, rs1247117, reveals changes in chromatin accessibility, PU.1 binding affinity and gene expression, and deletion of the genomic interval containing rs1247117 sensitizes cells to vincristine. Together, these data demonstrate that noncoding regulatory variants associated with diverse pharmacological traits harbor significant effects on allele-specific transcriptional activity and impact sensitivity to antileukemic agents.

28 July 2023 in Blood Advances
Verified
Journal Article
Open access
PDF file
BBBrennan P. Bergeron
Brennan P. Bergeron
KBKelly R. Barnett
Kelly R. Barnett
KBKashi Raj Bhattarai
Kashi Raj Bhattarai
RMRobert Jackson Mobley
Robert Jackson Mobley
BHBaranda S. Hansen
Baranda S. Hansen
DSDaniel Savic
Daniel Savic
Brennan P Bergeron, Kelly R Barnett, Kashi Raj Bhattarai, Robert Jackson Mobley, Jr., Baranda S Hansen, Anthony Brown, Kiran Kodali, Anthony Andrew High, Sima J

22 October 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
CICindy Im
Cindy Im
ARAndrew R. Raduski
Andrew R. Raduski
LMLauren J. Mills
Lauren J. Mills
KBKashi Raj Bhattarai
Kashi Raj Bhattarai
RMRobert Jackson Mobley
Robert Jackson Mobley
LSLogan Garrett Spector
Logan Garrett Spector
B-cell acute lymphoblastic leukemia (B-ALL) is the most common pediatric malignancy. Given racial/ethnic differences in incidence and outcomes, B-ALL genome-wide association studies among children of African ancestry are needed. Leveraging multi-institutional datasets with 840 African American children with B-ALL and 3360 controls, nine loci achieved genome-wide significance ( P < 5 × 10 −8 ) after meta-analysis. Two loci were established trans-ancestral susceptibility regions ( IKZF1 , ARID5B ), while the remaining novel loci were specific to African populations. Five-year overall survival among children carrying novel risk alleles was significantly worse (83% versus 96% in non-carriers, P = 4.8 × 10 −3 ). Novel risk variants were also associated with subtype-specific disease ( P < 0.05), including higher susceptibility for a subtype overrepresented in African American children ( TCF3-PBX1 ) and lower susceptibility for a subtype with excellent prognosis ( ETV6-RUNX1 ). Functional experiments revealed novel B-ALL risk variants had allele-specific differences in transcriptional activity ( P < 0.05) in B-cell and leukemia cell lines. These findings shed insights into ancestry-related differences in leukemogenesis and prognosis.

15 February 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
KBKelly R. Barnett
Kelly R. Barnett
RMRobert Jackson Mobley
Robert Jackson Mobley
JDJonathan D. Diedrich
Jonathan D. Diedrich
BBBrennan P. Bergeron
Brennan P. Bergeron
KBKashi Raj Bhattarai
Kashi Raj Bhattarai
DSDaniel Savic
Daniel Savic
SUMMARY: B-cell lineage acute lymphoblastic leukemia (B-ALL) is comprised of diverse molecular subtypes and while transcriptional and DNA methylation profiling of B-ALL subtypes has been extensively examined, the accompanying chromatin landscape is not well characterized for many subtypes. We therefore mapped chromatin accessibility using ATAC-seq for 10 B-ALL molecular subtypes in primary ALL cells from 154 patients. Comparisons with B-cell progenitors identified candidate B-ALL cell-of-origin and AP-1-associated cis -regulatory rewiring in B-ALL. Cis -regulatory rewiring promoted B-ALL-specific gene regulatory networks impacting oncogenic signaling pathways that perturb normal B-cell development. We also identified that over 20% of B-ALL accessible chromatin sites exhibit strong subtype enrichment, with transcription factor (TF) footprint profiling identifying candidate TFs that maintain subtype-specific chromatin architectures. Over 9000 inherited genetic variants were further uncovered that contribute to variability in chromatin accessibility among individual patient samples. Overall, our data suggest that distinct chromatin architectures are driven by diverse TFs and inherited genetic variants which promote unique gene regulatory networks that contribute to transcriptional differences among B-ALL subtypes. HIGHLIGHTS: Pro-B progenitor cells as the most common cell-of-origin for B-ALL AP-1 TF-associated cis -regulatory rewiring in B-ALL Subtype-specific accessible chromatin signatures representing 20% of all B-ALL sites Role for distinct TFs in promoting subtype-specific chromatin architectures Thousands of inherited genetic variants identified impacting chromatin state